IGLV2-34

Across TCGA pan-cancer cohorts, IGLV2-34 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGLV2-34 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGLV2-34 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV2-34 expression acts as an unfavorable survival marker.

LUAD are the cancer types where IGLV2-34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.313	0.812	.015	9	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

IGLV2-34–LUAD (OS)

Open the LUAD breakdown →